Literature DB >> 22996686

Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.

Michael R Abern1, William J Aronson, Martha K Terris, Christopher J Kane, Joseph C Presti, Christopher L Amling, Stephen J Freedland.   

Abstract

INTRODUCTION: Active surveillance (AS) is increasingly accepted as appropriate management for low-risk prostate cancer (PC) patients. It is unknown whether delaying radical prostatectomy (RP) is associated with increased risk of biochemical recurrence (BCR) for men with intermediate-risk PC.
METHODS: We performed a retrospective analysis of 1,561 low and intermediate-risk men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database treated with RP between 1988 and 2011. Patients were stratified by interval between diagnosis and RP (≤ 3, 3-6, 6-9, or >9 months) and by risk using the D'Amico classification. Cox proportional hazard models were used to analyze BCR. Logistic regression was used to analyze positive surgical margins (PSM), extracapsular extension (ECE), and pathologic upgrading.
RESULTS: Overall, 813 (52%) men were low-risk, and 748 (48%) intermediate-risk. Median follow-up among men without recurrence was 52.9 months, during which 437 men (38.9%) recurred. For low-risk men, RP delays were unrelated to BCR, ECE, PSM, or upgrading (all P > 0.05). For intermediate-risk men, however, delays >9 months were significantly related to BCR (HR: 2.10, P = 0.01) and PSM (OR: 4.08, P < 0.01). Delays >9 months were associated with BCR in subsets of intermediate-risk men with biopsy Gleason score ≤ 3 + 4 (HR: 2.51, P < 0.01), PSA ≤ 6 (HR: 2.82, P = 0.06), and low tumor volume (HR: 2.59, P = 0.06).
CONCLUSIONS: For low-risk men, delayed RP did not significantly affect outcome. For men with intermediate-risk disease, delays >9 months predicted greater BCR and PSM risk. If confirmed in future studies, this suggests delayed RP for intermediate-risk PC may compromise outcomes.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996686     DOI: 10.1002/pros.22582

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

1.  Prostate cancer outcomes and delays in care.

Authors:  Michael E O'Callaghan; Zumin Shi; Tina Kopsaftis; Kim Moretti
Journal:  Int Urol Nephrol       Date:  2017-01-12       Impact factor: 2.370

2.  Robotic prostatectomy and access to care: Canadian vs. U.S. experience.

Authors:  Kevin C Zorn; Marc Zanaty; Assaad El-Hakim
Journal:  Can Urol Assoc J       Date:  2016 May-Jun       Impact factor: 1.862

3.  Utilization and predictors of expectant management among elderly men with low-and intermediate-risk localized prostate cancer in U.S. urological practice.

Authors:  Huei-Ting Tsai; George Philips; Kathryn L Taylor; Keith Kowalczyk; Kuo Huai-Ching; Arnold L Potosky
Journal:  Urol Pract       Date:  2017-03

Review 4.  Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer.

Authors:  Christopher J Welty; Matthew R Cooperberg; Peter R Carroll
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

5.  Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.

Authors:  Jean Baptiste Beauval; Guillaume Ploussard; Bastien Cabarrou; Mathieu Roumiguié; Adil Ouzzane; Jérome Gas; Annabelle Goujon; Gautier Marcq; Romain Mathieu; Sébastien Vincendeau; Xavier Cathelineau; Pierre Mongiat-Artus; Laurent Salomon; Michel Soulié; Arnaud Méjean; Alexandre de La Taille; Morgan Rouprêt; François Rozet
Journal:  World J Urol       Date:  2016-12-16       Impact factor: 4.226

6.  Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Authors:  Shivanshu Awasthi; Travis Gerke; Jong Y Park; Francis A Asamoah; Vonetta L Williams; Angelina K Fink; Rajesh Balkrishnan; David I Lee; S Bruce Malkowicz; Priti Lal; Jasreman Dhillon; Julio M Pow-Sang; Timothy R Rebbeck; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-09       Impact factor: 4.254

7.  Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?

Authors:  Mariana Andozia Morini; Roberto Lodeiro Muller; Paulo César Barbosa de Castro Junior; Rafael José de Souza; Eliney Ferreira Faria
Journal:  World J Urol       Date:  2018-03-16       Impact factor: 4.226

8.  Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Authors:  Kirsti Aas; Sophie Dorothea Fosså; Rune Kvåle; Bjørn Møller; Tor Åge Myklebust; Ljiljana Vlatkovic; Stig Müller; Viktor Berge
Journal:  World J Urol       Date:  2018-11-27       Impact factor: 4.226

Review 9.  Timing of curative treatment for prostate cancer: a systematic review.

Authors:  Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

Review 10.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.